Next 10 |
2024-06-27 10:38:07 ET Summary Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025. Bla...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Vell...
2024-05-16 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-09 07:54:56 ET More on Black Diamond Therapeutics Seeking Alpha’s Quant Rating on Black Diamond Therapeutics Historical earnings data for Black Diamond Therapeutics Financial information for Black Diamond Therapeutics Read the full article on...
Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024 Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025 Presented real world evidence on the evolving EGFR mutation landscap...
2024-04-27 14:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024...
2024-04-08 08:00:07 ET Robert Driscoll from Wedbush issued a price target of $16.00 for BDTX on 2024-04-08 07:07:00. The adjusted price target was set to $16.00. At the time of the announcement, BDTX was trading at $5.06. The overall price target consensus is at $12.00 w...
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Vell...